Written by Daniel Mollenkamp || 13th February 2018 || Regulatory briefing || Health and science | Policy and Politics | Regulation and Legislation | Geographies: North America United States Ten US Senators have urged the FDA to reject PMI's reduced risk application for IQOS following the findings of the independent Tobacco Products Scientific Advisory Committee (TPSAC) ... Are you already a subscriber? login here Login Username or Email Password Remember me Forget? | Register Username or Email Back to Login | Register Enjoy free subscription accessGet access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors. I want a free trial Benefits of subscription plans:Stay informed of any legal and market change in the sector that impacts your organizationMaximise resources by getting market and legal data analysis daily in one placeMake smart decisions by understanding how the regulatory and market landscape evolvesAnticipate risks in your decisions by monitoring regulatory changes that impact your organizationNeed help?Contact a sales representative right now and don’t waitErik Galavis +34 654 320 547 Email Erik Related contents Could the TPD allow for reduced-risk claims? FDA committee rejects two IQOS MRTP claims, approves one Has Reuters’ IQOS investigation crucially dented PMI’s reputation?